Mydecine Innovations Group Stock Performance
| MYCOF Stock | USD 0 0 44.00% |
Mydecine Innovations holds a performance score of 9 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -5.34, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Mydecine Innovations are expected to decrease by larger amounts. On the other hand, during market turmoil, Mydecine Innovations is expected to outperform it. Use Mydecine Innovations information ratio, downside variance, day typical price, as well as the relationship between the treynor ratio and kurtosis , to analyze future returns on Mydecine Innovations.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Mydecine Innovations Group are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly inconsistent basic indicators, Mydecine Innovations reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.2 M | |
| Total Cashflows From Investing Activities | -473.6 K |
Mydecine |
Mydecine Innovations Relative Risk vs. Return Landscape
If you would invest 0.70 in Mydecine Innovations Group on September 27, 2024 and sell it today you would lose (0.20) from holding Mydecine Innovations Group or give up 28.57% of portfolio value over 90 days. Mydecine Innovations Group is currently producing 4.1989% returns and takes up 33.2584% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Mydecine, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Mydecine Innovations Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mydecine Innovations' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Mydecine Innovations Group, and traders can use it to determine the average amount a Mydecine Innovations' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1262
| Best Portfolio | Best Equity | MYCOF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 33.26 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.2 actual daily | 83 83% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Mydecine Innovations is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mydecine Innovations by adding it to a well-diversified portfolio.
Mydecine Innovations Fundamentals Growth
Mydecine Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Mydecine Innovations, and Mydecine Innovations fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mydecine Pink Sheet performance.
| Return On Equity | -12.24 | |||
| Return On Asset | -1.76 | |||
| Current Valuation | 8.64 M | |||
| Shares Outstanding | 13.01 M | |||
| Price To Book | 23.41 X | |||
| Price To Sales | 677.59 X | |||
| Revenue | 7.49 K | |||
| EBITDA | (23.14 M) | |||
| Cash And Equivalents | 324.15 K | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 4.35 M | |||
| Debt To Equity | 0.06 % | |||
| Book Value Per Share | (0.36) X | |||
| Cash Flow From Operations | (24.05 M) | |||
| Earnings Per Share | (4.68) X | |||
| Total Asset | 7.58 M | |||
About Mydecine Innovations Performance
By analyzing Mydecine Innovations' fundamental ratios, stakeholders can gain valuable insights into Mydecine Innovations' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Mydecine Innovations has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mydecine Innovations has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Mydecine Innovations operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 11 people.Things to note about Mydecine Innovations performance evaluation
Checking the ongoing alerts about Mydecine Innovations for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Mydecine Innovations help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mydecine Innovations is way too risky over 90 days horizon | |
| Mydecine Innovations has some characteristics of a very speculative penny stock | |
| Mydecine Innovations appears to be risky and price may revert if volatility continues | |
| Mydecine Innovations has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 7.49 K. Net Loss for the year was (28.9 M) with profit before overhead, payroll, taxes, and interest of 7.49 K. | |
| Mydecine Innovations Group has accumulated about 324.15 K in cash with (24.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Mydecine Innovations' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mydecine Innovations' stock is overvalued or undervalued compared to its peers.
- Examining Mydecine Innovations' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mydecine Innovations' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mydecine Innovations' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mydecine Innovations' pink sheet. These opinions can provide insight into Mydecine Innovations' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Mydecine Pink Sheet analysis
When running Mydecine Innovations' price analysis, check to measure Mydecine Innovations' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mydecine Innovations is operating at the current time. Most of Mydecine Innovations' value examination focuses on studying past and present price action to predict the probability of Mydecine Innovations' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mydecine Innovations' price. Additionally, you may evaluate how the addition of Mydecine Innovations to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |